|
|
RC529 vaccine adjuvant |
|
Vaxjo ID |
74 |
|
Vaccine Adjuvant Name |
RC529 vaccine adjuvant |
|
Adjuvant VO ID |
VO_0001239
|
|
Description |
RC529 is a lipid A mimetic |
|
Stage of Development |
Clinical Trial |
|
Components |
RC-529 compound is a 2-[(R)-3-tetradecanoyloxytetradecanoylamino]ethyl 2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyoxytetradecanoyl]-2-[(R)-3-tetradecanoyoxytetradecanoylamino]-β-D-glucopyranos idetriethylammonium salt |
|
Function |
Like LPS and MPL, RC529 has been shown to signal through TLR4, resulting in the up-regulation of cell-surface costimulatory molecules and receptors, cytokines, and chemokines (Thompson et al., 2005). |
|
Safety |
RC529 was shown to be well-tolerated and effective during a clinical trial in which healthy patients were given a vaccine against hepatitis B (Thompson et al., 2005). |
| Related Vaccine(s) |
|
| References |
Thompson et al., 2005: Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell TC. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. Journal of leukocyte biology. 2005; 78(6); 1273-1280. [PubMed: 16204643].
|
|
